(VIANEWS) – Shares of Exact Sciences (NASDAQ: EXAS) rose by a staggering 28% in 21 sessions from $64.07 at 2023-04-28, to $82.01 at 11:42 EST on Monday, following the last session’s upward trend. NASDAQ is rising 2.19% to $12,975.69, after two successive sessions in a row of gains.
Exact Sciences’s last close was $82.01, 4.44% below its 52-week high of $85.82.
About Exact Sciences
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Earnings Per Share
As for profitability, Exact Sciences has a trailing twelve months EPS of $-2.96.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -16.36%.
Sales Growth
Exact Sciences’s sales growth is 14.8% for the current quarter and 14.9% for the next.
Volatility
Exact Sciences’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.49%, a positive 1.27%, and a positive 2.11%.
Exact Sciences’s highest amplitude of average volatility was 1.53% (last week), 2.21% (last month), and 2.11% (last quarter).
More news about Exact Sciences (EXAS).
